<DOC>
	<DOCNO>NCT01710488</DOCNO>
	<brief_summary>The primary objective study determine percentage patient `` therapeutic success '' end cycle antibiotic therapy ( 10 day ) , two treatment group ( levofloxacin prulifloxacin ) . The effect study treatment evaluate basis score determine relation signs-symptoms acute exacerbation COPD ( sputum purulence , sputum volume , cough , dyspnea , fever )</brief_summary>
	<brief_title>Comparison Between Levofloxacin Prulifloxacin , Internal Medicine Patients With Acute Exacerbation COPD</brief_title>
	<detailed_description>The aim study examine effect use fluoroquinolones class antibiotic introduce relatively recently , particular population patient acute exacerbation COPD , previously treat unsuccessfully antibiotic , hospitalize Internal Medicine . These patient reflect reality patient admit Internal Medicine , characterize high frequency advance age , polypathology , multiple treatment .</detailed_description>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Prulifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>Presence purulent sputum document colorimetric assay ( Allegra et al. , Resp Med 2005 ) , plus least two follow signssymptoms Increased cough Increased dyspnea Increase sputum volume appear least 3 day previous antibiotic treatment medication ( eg , amoxicillin , amoxicillin / clavulanate , cephalosporins macrolides ) exception quinolones , conduct least 3 day persistence worsen symptom subsequent use hospital ≥ 60 year FEV1 &lt; 80 % ≥ 30 % ratio FEV 1 / FVC &lt; 70 % chest xray negative inflammatory infiltrates inform consent asthma pulmonary neoplasms history allergy hypersensitivity quinolones impracticability oral antibiotic / alter ability absorption gastrointestinal system history epilepsy , seizure , cerebral vascular disease ( stroke cerebri within 6 month ) history tendinopathy note severe renal impairment creatinine &gt; twice upper limit normal range hepatic impairment ( AST / ALT &gt; twice upper limit normal range ) patient sepsis , tuberculosis infection organs system cystic fibrosis patient inherit tolerance intolerance , Lapp lactase deficiency glucosegalactose malabsorption , deficiency enzyme glucose6phosphate dehydrogenase pregnant breastfeed drug alcohol addiction experimental concomitant treatment drug</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>COPD exacerbation</keyword>
	<keyword>fluoroquinolones ,</keyword>
</DOC>